Research Waste in Degenerative Spinal Disease Trials: 80% Show Quality Concerns

Could Research Waste in DSD Trials Affect Clinical Outcomes?

Degenerative spinal disease (DSD) clinical trials show alarming rates of research waste, according to a comprehensive analysis of 335 randomized controlled trials (RCTs) registered on ClinicalTrials.gov over the past three decades. The study, published in Scientific Reports, found that nearly 80% of completed DSD trials exhibited at least one characteristic of research waste—a concerning statistic given the substantial global disease burden associated with these conditions. With low back and neck pain ranking among the top ten causes of years lived with disability (YLDs) worldwide and affecting approximately 865 million people as of 2017, the findings highlight significant inefficiencies in the clinical research landscape for spinal disorders. The researchers identified several key factors that influence research waste, including study design elements, funding sources, and trial implementation approaches, providing valuable insights for future trial development in this therapeutic area.

The study, which included trials registered between January 1995 and July 2024, demonstrated notable shifts in research focus over time. Early trials predominantly investigated surgical interventions, but recent years have seen a significant increase in RCTs examining physical therapy approaches. Between 1995 and 1999, all eight identified trials focused on surgical interventions, whereas by 2020-2024, surgical studies comprised only 18.7% of trials, with physical therapy studies increasing to 42.7%. This evolution reflects the growing interest in non-invasive treatment options for DSDs, particularly as concerns about surgical complications such as adjacent segment degeneration and spinal instability have emerged. Additionally, the geographic distribution of research has shifted dramatically, with North American institutions conducting 69.8% of trials before 2010, while non-North American regions led 79.5% of trials after 2010. These temporal and geographic trends illustrate the dynamic nature of DSD research and highlight the global interest in addressing these prevalent conditions.

How Do Researchers Define and Measure Waste?

The investigators defined research waste using three primary criteria: nonpublication (completed trials without published results), reporting limitations (published trials meeting less than 75% of CONSORT statement items), and high risk of bias (less than 50% of items classified as low risk using Cochrane tools). After excluding trials completed after December 2017 to allow sufficient time for publication, the analysis revealed that 78.13% of the 224 eligible RCTs exhibited at least one characteristic of research waste. Specifically, 21.4% remained unpublished, 71.59% of published trials had reporting limitations, and 40.34% demonstrated a high risk of bias. Common reporting deficiencies included inadequate descriptions of randomization methods, allocation concealment, outcome measure reporting formats, and intention-to-treat analysis. For non-pharmacological trials, additional limitations involved insufficient reporting on customization of participant treatment plans and evaluation of treatment plan compliance. These findings underscore significant gaps in the transparency and methodological rigor of DSD clinical research, potentially limiting the utility of trial results for informing clinical practice.

Through multivariate logistic regression analysis, the researchers identified several factors associated with reduced likelihood of research waste. Trials implementing blinding protocols showed substantially lower odds of research waste compared to open-label studies (OR 0.10 for single-blind; OR 0.14 for double-blind or greater). Similarly, studies conducted without industry funding demonstrated significantly lower odds of research waste (OR 0.13) compared to industry-funded trials. Multicenter trials also exhibited lower odds of research waste (OR 0.22) compared to single-center studies. These findings suggest that specific methodological choices and structural factors can significantly influence the scientific value and utility of DSD research. Interestingly, sample size did not demonstrate a significant relationship with research waste, indicating that even smaller studies can produce valuable evidence when properly designed and reported. The identification of these factors provides actionable insights for researchers and sponsors seeking to maximize the impact of future clinical trials in degenerative spinal conditions.

Are DSD Trials Influencing Clinical Guidelines and Further Research?

Beyond assessing research waste, the study evaluated the broader impact of published trials by examining their citation in clinical guidelines and reuse of prospective data. Among trials published before 2017, 51.7% were cited in clinical guidelines, with North American studies more likely to be referenced—possibly reflecting the earlier establishment of evidence-based medicine frameworks in this region. Additionally, 25.57% of published trials reused prospective data for post-hoc analyses, with larger studies (sample size ≥200) more likely to generate additional analyses. These metrics provide important context about the downstream utilization of clinical trial evidence and highlight potential opportunities to enhance the value of completed research. The findings suggest that while research waste remains prevalent, a substantial proportion of DSD trials do contribute meaningfully to clinical practice guidelines and generate data that supports additional scientific inquiry. Maximizing these positive outcomes while minimizing waste represents a critical challenge for the spinal research community.

What Challenges and Future Directions Remain for DSD Research?

The authors acknowledged several limitations in their analysis, including their focus on a single trial registration platform (ClinicalTrials.gov), exclusion of incomplete or terminated trials, and potential underestimation of publication rates due to the exclusion of trials completed after December 2017. Additionally, they noted that their definition of research waste represented a minimal concept and that actual waste might exceed their estimates. Despite these limitations, the study provides valuable insights into the current state of DSD clinical research and identifies opportunities for improvement. The authors emphasized the importance of enhancing research design, implementation, reporting, and data reuse to reduce future waste. Given the increasing global burden of degenerative spinal diseases, particularly with aging populations, optimizing the efficiency and quality of clinical trials represents a crucial priority for advancing effective treatment strategies and improving patient outcomes in this field.

The findings raise important questions about how the spinal research community should address these challenges moving forward. Could standardized reporting templates specifically tailored to surgical and physical therapy interventions help improve adherence to CONSORT guidelines? How might funding agencies and journals collaborate to incentivize more rigorous methodological approaches in DSD trials? What role should regulatory bodies play in establishing minimum quality standards for trial registration and reporting? As the prevalence and burden of degenerative spinal conditions continue to increase globally, addressing these questions becomes increasingly urgent to ensure that limited research resources generate meaningful evidence to guide clinical practice and improve patient outcomes.

Summary

A comprehensive analysis of 335 randomized controlled trials examining degenerative spinal disease treatments reveals that nearly 80% of completed studies exhibited characteristics of research waste, including nonpublication, inadequate reporting, or high risk of bias. The study, which analyzed trials registered on ClinicalTrials.gov between 1995 and 2024, found that specific design elements significantly influence research quality: trials implementing blinding protocols, those conducted without industry funding, and multicenter studies all demonstrated substantially lower odds of research waste. Over the three-decade period, research focus shifted dramatically from predominantly surgical interventions to increasing emphasis on physical therapy approaches, while geographic distribution expanded from North American dominance to global participation. Among published trials completed before 2017, approximately half were cited in clinical guidelines and a quarter generated additional post-hoc analyses, indicating meaningful downstream impact despite prevalent waste. The findings highlight critical inefficiencies in spinal disease research—particularly concerning given that low back and neck pain affect approximately 865 million people worldwide and rank among the top ten causes of disability. The researchers emphasize that improving trial design, implementation, reporting standards, and data reuse represents an urgent priority for maximizing research value and advancing effective treatment strategies for degenerative spinal conditions as global disease burden continues to increase with aging populations.